Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 4/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | CPB1 | P15086 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | TGM2 | P21980 | 5/20 | 0.42 |
| ▸ | F13A1 | P00488 | 3/20 | 0.42 |
| ▸ | TGM1 | P22735 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL207913 | 0.83 | CTSL (0.47) | PDE4BCTSLCPB1CTSBCTSK | |
| SCHEMBL209968 | 0.82 | DRD2 (0.50) | PDE4BCTSLCPB1CTSBCTSK | |
| SCHEMBL206802 | 0.81 | KMT2A (0.47) | PDE4BCTSLCPB1CTSBCTSK | |
| SCHEMBL4263739 | 0.81 | PDE4B (0.49) | PDE4BCTSLCPB1CTSBCTSK | |
| SCHEMBL210039 | 0.81 | PDE4B (0.49) | PDE4BCTSLCPB1CTSBCTSK | |
| SCHEMBL208375 | 0.81 | CTSL (0.46) | PDE4BCTSLCPB1CTSBCTSK | |
| SCHEMBL4268253 | 0.81 | PDE4B (0.49) | PDE4BCTSLCPB1CTSBCTSK | |
| SCHEMBL207775 | 0.81 | PDE4B (0.53) | PDE4BCTSLCPB1CTSBCTSK | |
| SCHEMBL3563686 | 0.79 | KMT2A (0.56) | PDE4BCTSLCPB1CTSBCTSK | |
| SCHEMBL4033681 | 0.79 | CPB1 (0.54) | PDE4BCTSLCPB1CTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088796-B2 | Triamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-8088796-B2 | Triamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20090239857-A1 | TRIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090239857-A1 | TRIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1864982-A1 | TRIAMINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239857-A1 | TRIAMINE DERIVATIVE | F2, F12, F3 | RORC 4088/4885PDE4B 3937/4885CTSL 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.